感染

订阅

MedSci主页 / 所有栏目 / 感染

RNAi疗法对抗2019-nCoV：Sirnaomics推进基于RNAi的预防和治疗方法

2020-01-25 Allan MedSci原创

RNAi2019-nCoVSirnaomics
关注

Sirnaomics是发现和开发新型RNAi疗法的领先生物制药公司，今日宣布，它已动员其在美国和中国的研究团队开发基于RNAi的新型预防剂和疗法来对抗2019-nCoV引起的严重急性呼吸道感染（SARI）。

Sirnaomics是发现和开发新型RNAi疗法的领先生物制药公司，今日宣布，它已动员其在美国和中国的研究团队开发基于RNAi的新型预防剂和疗法来对抗2019-nCoV引起的严重急性呼吸道感染（SARI）。截至目前（2020年1月25日19:41），2019-nCoV确诊的患者总数为1399例，41例死亡。

Sirnaomics研发团队曾使用siRNA预防和治疗SARS冠状病毒、H5N1流感和其他呼吸道病毒感染，并具有多种动物模型，包括非人类灵长类动物。为了对抗由2019-nCoV感染引起的SARI，Sirnaomics团队已经确定了潜在有效的siRNA，特别针对病毒感染和复制至关重要的病毒基因。


原始出处：

https://www.firstwordpharma.com/node/1696054

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 08 11:49:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024071, encodeId=e0e220240e1e3, content=<a href='/topic/show?id=f6d51633365' target=_blank style='color:#2F92EE;'>#Sirnaomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16333, encryptionId=f6d51633365, topicName=Sirnaomics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 06:49:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399284, encodeId=4a4a13992845f, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548204, encodeId=11831548204ab, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378506, encodeId=da653e8506f2, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 25 22:01:20 CST 2020, time=2020-01-25, status=1, ipAttribution=)]
    2020-09-08 yinxm8315

    #RNAi#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 08 11:49:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024071, encodeId=e0e220240e1e3, content=<a href='/topic/show?id=f6d51633365' target=_blank style='color:#2F92EE;'>#Sirnaomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16333, encryptionId=f6d51633365, topicName=Sirnaomics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 06:49:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399284, encodeId=4a4a13992845f, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548204, encodeId=11831548204ab, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378506, encodeId=da653e8506f2, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 25 22:01:20 CST 2020, time=2020-01-25, status=1, ipAttribution=)]
    2020-08-14 guojianrong

    #Sirnaomics#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 08 11:49:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024071, encodeId=e0e220240e1e3, content=<a href='/topic/show?id=f6d51633365' target=_blank style='color:#2F92EE;'>#Sirnaomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16333, encryptionId=f6d51633365, topicName=Sirnaomics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 06:49:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399284, encodeId=4a4a13992845f, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548204, encodeId=11831548204ab, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378506, encodeId=da653e8506f2, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 25 22:01:20 CST 2020, time=2020-01-25, status=1, ipAttribution=)]
    2020-01-27 showtest

    #治疗方法#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 08 11:49:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024071, encodeId=e0e220240e1e3, content=<a href='/topic/show?id=f6d51633365' target=_blank style='color:#2F92EE;'>#Sirnaomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16333, encryptionId=f6d51633365, topicName=Sirnaomics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 06:49:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399284, encodeId=4a4a13992845f, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548204, encodeId=11831548204ab, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378506, encodeId=da653e8506f2, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 25 22:01:20 CST 2020, time=2020-01-25, status=1, ipAttribution=)]
    2020-01-27 12498ebem23暂无昵称

    #siRNA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1751673, encodeId=61581e51673aa, content=<a href='/topic/show?id=2c2c1553e56' target=_blank style='color:#2F92EE;'>#RNAi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15537, encryptionId=2c2c1553e56, topicName=RNAi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d436366397, createdName=yinxm8315, createdTime=Tue Sep 08 11:49:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024071, encodeId=e0e220240e1e3, content=<a href='/topic/show?id=f6d51633365' target=_blank style='color:#2F92EE;'>#Sirnaomics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16333, encryptionId=f6d51633365, topicName=Sirnaomics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Aug 14 06:49:00 CST 2020, time=2020-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399284, encodeId=4a4a13992845f, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548204, encodeId=11831548204ab, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Mon Jan 27 10:49:00 CST 2020, time=2020-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378506, encodeId=da653e8506f2, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Jan 25 22:01:20 CST 2020, time=2020-01-25, status=1, ipAttribution=)]
    2020-01-25 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

相关资讯

Nat Biotechnol：RNAi疗法减轻先兆子痫

来自麻省大学医学院、贝斯以色列女执事医学中心和西悉尼大学的科学家合作研究表明，使用小干扰RNA新型疗法（siRNA）在动物模型中减轻了先兆子痫症状。

RNAi疗法givosiran治疗急性肝性卟啉症的晚期研究达到主要终点

Alnylam制药本周三（2019年3月6日）报道，用于治疗急性肝性卟啉症（AHP）的研究性RNAi疗法givosiran的III期研究符合其主要疗效终点和许多次要目标。

Circulation：RNAi疗法治疗限制性心肌病的临床前景

限制性心肌病是一种罕见的与肉瘤基因突变相关的心脏病，与表型肥厚性心肌病有所重叠。目前尚无针对潜在病因的有效治疗方法。干扰RNA (RNAi)是否可治疗MYL2突变所致的限制性心肌病？研究人员根据有效性和特异性筛选出一个短的发夹结构RNA（M7.8）。两组肌球蛋白调控轻链N47K转基因小鼠分别于3日龄和60日龄时注射腺病毒9包装的M7.8L。治疗后让小鼠进行平板运动，并予以超声心动图检查，以确定最大

FDA批准**RNAi药物Onpattro用于治疗hATTR

日前，美国FDA批准了一项具有里程碑意义的基因疗法，针对罕见病遗传性转甲状腺素蛋白淀粉样变性或hATTR(一种神经病变或神经损伤)的基因疗法。这也是全球第一例依据诺贝尔奖成果RNA干扰技术开发的药物Onpattro，该药作用机理通过使致病基因“沉默”，进而从根本上治愈该罕见遗传疾病。也是FDA批准的首款小干扰RNA（siRNA）药物。hATTR影响了全球约50000人，是一种罕见、使人衰弱且常

Alnylam的RNAi疗法Onpattro获得欧盟批准治疗hATTR

Alnylam Pharmaceuticals于本周四宣布，该公司开发的Onpattro（patisiran）的获得欧盟的上市许可，用于治疗遗传性转甲状腺素蛋白淀粉样变性（hATTR）的1或2期多发性神经病变的成年患者。该公司指出，该药物在2018年8月11日被FDA批准后，现在再次获得欧盟批准，成为欧盟批准的首个RNAi疗法。

20年等待！FDA批准基于诺奖技术的新疗法

8月10日，美国FDA宣布批准第一款基于RNA干扰（RNAi）技术的治疗药物——patisiran，适用于一种损伤心脏、神经功能的罕见病。其中，RNAi技术可以针对性沉默与疾病相关的特定基因，从而阻止致病蛋白的表达。